文献速递心脑血管急症

急诊0/1小时与0/3小时心肌梗死路径的安全性与有效性:一项国际实用性阶梯楔形整群随机对照试验

Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial.
PubMed 文献 · Lancet · 2026-08-29
一句话结论在尚未采用0/1小时路径的医院中,实施0/1小时路径对30天死亡或新发1型心梗复合终点非劣于0/3小时路径,但未缩短急诊停留时间。

以0/3小时路径(0 h和3 h抽血)为标准治疗的医院随机在6个月(早期实施)或12个月(晚期实施)后实施0/1小时路径(0 h和1 h抽血)。全分析集共67 624例就诊(0/3 h组36 464例,0/1 h组31 160例)。实施0/1小时路径达到预设非劣效标准,但未缩短急诊停留时间,单靠实施该路径不应期望改善急诊吞吐量。

要点

  • 该试验仅纳入因急性非创伤性胸部不适疑似心肌梗死连续就诊的成人,排除人群原文未提及。
  • 结论:单靠实施0/1小时路径不应期望改善急诊吞吐量,需配合其他流程改进。

适用人群与场景

  • 连续就诊于急诊科的成人(中位年龄59岁,IQR 46-73),表现为急性非创伤性胸部不适且疑似心肌梗死。

诊断标准与关键阈值

  • 疑似心肌梗死评估依赖高敏肌钙蛋白系列检测。
  • 0/1小时路径定义为0 h和1 h抽血;0/3小时路径定义为0 h和3 h抽血。

处置流程与药物剂量

  • 第一步:对疑似心梗的急诊成人,按所在路径在0 h抽血检测高敏肌钙蛋白。
  • 第二步:0/1 h路径在1 h再次抽血;0/3 h路径在3 h再次抽血。
  • 原文未提及具体药物剂量、给药途径、频次或目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 干预与对照:0/1 h路径(31 160例) vs 0/3 h路径(36 464例);医院随机在6个月(早期)或12个月(晚期)后实施0/1 h路径。

证据类型、等级与局限

  • 证据类型:国际、实用性、阶梯楔形、整群随机、对照、终点设盲试验。
  • 局限:原文未明确列出局限;设计上为整群随机、阶梯楔形、实用性试验,终点设盲。

对床旁实践的改变

  • 在尚未采用0/1小时路径的医院,实施0/1小时路径不增加30天死亡或新发1型心梗风险,可安全替代0/3小时路径。
  • 但单靠实施0/1小时路径不能缩短急诊停留时间,不应期望其改善急诊吞吐量。
  • 适用人群为急诊就诊的急性非创伤性胸部不适疑似心肌梗死成人;不适用人群原文未提及。

指南或共识出处

  • PRESC1SE-MI试验,注册号ClinicalTrials.gov NCT05649384;发表于Lancet。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: The evaluation of patients with suspected myocardial infarction relies on serial measurements of high-sensitivity cardiac troponin. We aimed to evaluate the safety and efficacy of implementing the guideline-recommended 0/1 h pathway, compared with a 0/3 h pathway, in hospitals that had not yet adopted the newer strategy.

METHODS: PRESC1SE-MI was an international, pragmatic, stepped-wedge, cluster-randomised, controlled, masked-endpoint trial at 19 hospitals in ten countries. The study included consecutive adults presenting to the emergency department with acute non-traumatic chest discomfort and suspected myocardial infarction. Hospitals using a 0/3 h pathway (blood draws at 0 h and 3 h) as standard care were randomly allocated to implement the 0/1 h pathway (blood draws at 0 h and 1 h) after 6 months (early implementation) or 12 months (late implementation). The trial was designed to test the non-inferiority of the 0/1 h pathway for safety and its superiority for efficacy. The non-inferiority margin was set at an odds ratio of 1·3. Analyses were done in the full analysis set. The coprimary safety outcome was a composite of death from any cause or new type 1 myocardial infarction within 30 days, and the coprimary efficacy outcome was emergency department length of stay. This trial is registered with ClinicalTrials.gov, NCT05649384, and is active but no longer enrolling.

FINDINGS: Between Dec 1, 2020, and Dec 31, 2024, 71 983 consecutive patient presentations were screened, of which 67 624 (93·9%) met the eligibility criteria and comprised the full analysis set. Median age was 59 years (IQR 46-73); 29 954 (44·3%) patient presentations were in female patients and 37 670 (55·7%) were in male patients. 13 753 (22·2%) of 62 060 patient presentations with available data were in patients with known coronary artery disease, and 5855 (8·7%) patient presentations had an adjudicated index diagnosis of myocardial infarction. Overall, 36 464 patient presentations were managed with a 0/3 h pathway and 31 160 with the 0/1 h pathway. Death from any cause or new type 1 myocardial infarction occurred in 454 (1·2%) patient presentations in the 0/3 h group and in 341 (1·1%) patient presentations in the 0/1 h group (adjusted odds ratio 0·93 [95% CI 0·77-1·13]; pnon-inferiority=0·0004). The median emergency department length of stay was 309 min (IQR 203-470) in the 0/3 h pathway and 309 min (207-474) in the 0/1 h pathway (ratio of adjusted median times 1·00 [95% CI 0·97-1·02]; two-sided p=0·65).

INTERPRETATION: Implementation of the 0/1 h pathway met the prespecified non-inferiority criterion for the 30-day composite safety outcome but did not shorten emergency department length of stay compared with the 0/3 h pathway. In this setting, implementation of the 0/1 h pathway alone should therefore not be expected to improve emergency department throughput.

FUNDING: Swiss National Science Foundation, Swiss Heart Foundation, University Hospital Basel, University of Basel, Foundation for Cardiovascular Research Basel, Fondazione Ricerca Molinette, Idorsia, and Roche.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Boeddinghaus J, Bima P, Crisanti L, et al. Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial. Lancet. 2026. PMID: 42667934. doi:10.1016/S0140-6736(26)01654-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。